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Abstract 
Renal tubulopathies are fascinating disorders that provide insights into the inner workings of 
the kidney, yet also pose therapeutic challenges. Due to the central nature of sodium in 
tubular transport physiology, disorders of sodium handling can be especially challenging, as 
they may affect virtually all aspects of the homeostatic functions of the kidney. Yet, owing to 
their rarity, little clinical evidence with regards to treatment exists. Consequently, treatment 
can vary widely in between individual physicians and centers and is based mainly on 
understanding of renal physiology, reported clinical observations, as well as individual 
experiences. Salt-losing tubulopathies can affect all tubular segments, from the proximal 
tubule to the collecting duct. But the more frequently seen disorders are Bartter and 
Gitelman syndrome affecting salt transport in the thick ascending limb of Henle’s loop and/or 
the distal convoluted tubule and these disorders generate the greatest controversies 
regarding their management Here we review clinical and molecular aspects of salt-losing 
tubulopathies and discuss novel insights, provided mainly by genetic investigations and 
retrospective clinical reviews. In addition, we discuss controversial topics in the 
management of these disorders to highlight areas of importance for future clinical trials. 
International collaboration will be required to perform clinical studies to inform the treatment 
of these rare disorders. 
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Introduction 
The preservation of electrolyte, volume and acid-base homeostasis balance is vital to the 
functioning of our bodies. As life initially evolved in the ocean, cellular function is dependent 
on the maintenance of the electrolyte concentration reflective of the original environment. No 
idea could be thought, no muscle moved without the proper balance of salts within our 
body.1 It is the responsibility of mainly the kidneys to maintain this vital ‘milieu interieur’. The 
kidneys do so by the combination of glomerular filtration and tubular reabsorption, a system 
that is best explained by the evolutionary history. “Intelligent design” may not have devised a 
system, that, in an average adult, initially filters approximately 150 liters of water daily 
containing an enormous load of solutes, including about 20,000 mmol of sodium per day 
(equivalent to the amount in 1.2 kg of cooking salt), only to laboriously reabsorb virtually all 
of it back into circulation. In the original ocean environment, a system of filtration was well 
suited given the unlimited availability of salt and water. Yet, in order to enable life on land, 
large losses of water and solutes had to be prevented, leading to the evolution of ever more 
powerful tubules.2 Under physiological conditions, they are capable of reabsorbing more 
than 99% of filtered sodium and water. This enormous task is accomplished by a 
combination of distinct sodium or sodium-coupled transport systems along the nephron. It is 
the active reabsorption of sodium that generates the main driving force for the passive 
reabsorption of water. The price to pay for this powerful system of filtration and reabsorption 
is a high-energy demand: when adjusted for organ weight, the kidneys, together with the 
heart, have the highest resting metabolic expenditure, approximately 440 kcal/kg/d, almost 
twice as much as the brain, making the kidneys susceptible to acute injury when the energy 
supply is impaired.3  
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The importance of tubular sodium reabsorption becomes especially apparent, when the 
system is disturbed, as in the salt-losing tubulopathies.  
Based on anatomic and functional characteristics, the tubules are typically divided into 
four main segments: proximal tubule, loop of Henle, distal convoluted tubule and collecting 
duct. Genetic or acquired defects in salt transport in any of these segments lead to distinct 
tubulopathies, which have characteristic clinical and biochemical features (fig. 1).  
Interestingly, given the critical nature of sodium for the maintenance of volume 
homeostasis, essentially all salt-losing tubulopathies actually maintain normal sodium 
excretion in steady state, as persistent losses exceeding intake would be incompatible with 
life. This normal sodium excretion is achieved by a compensatory increase in absorption 
through other pathways. This explains the commonly seen hyperaldosteronism that 
characterizes for instance Bartter and Gitelman syndromes, which enhances sodium 
reabsorption in the collecting duct, primarily at the expense of potassium secretion. 
Consequently, a key diagnostic feature for renal salt wasting is the fractional excretion of 
chloride.4 
Here we will review key advances in our understanding of the different renal genetic 
disorders affecting salt (sodium chloride) reabsorption with respect to both clinical 
phenotype and underlying pathophysiology. An overview of these disorders, the underlying 
genes and key clinical characteristics is given in table 1. In addition, we will highlight some 
clinical controversies around the treatment of salt-losing tubulopathies, which need further 
clinical studies and which are summarized in table 2.  
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Proximal Tubule 
The proximal tubule (PT) is the part of the nephron where the most diverse action with 
respect to reabsorption (as well as secretion) takes place (fig. 2). Micropuncture studies 
suggest that between 60-80% of all filtered salt and water is reabsorbed in this segment.5 
The “engine” for salt transport, as in all tubular segments, is the basolateral Na+-K+-ATPase, 
which establishes the electrochemical gradient for sodium entry into the cell. The Fanconi 
renal tubular syndrome (FRTS) represents global dysfunction of the PT and, due to the high 
energy demand of this transport process is often associated with disorders of impaired 
energy supply, such as mitochondrial cytopathies.6 But aside from being a secondary 
feature of systemic disorders, FRTS can also occur in primary form. Currently, OMIM lists 3 
such forms of FRTS (see table 1): FRTS1 is dominantly inherited and typically presents in 
childhood with rickets and the typical biochemical abnormalities of FRTS. Progressive 
chronic kidney disease (CKD) is typically observed with development of CKD stage 5 in 
adulthood. While the underlying gene has been linked to a locus on chromosome 15, the 
identity of this gene remains to be revealed.7 FRTS2 previously referred to FRTS observed 
in 2 siblings with a homozygous mutation in SLC34A1.8 Yet, recessive mutations in this 
gene were subsequently found to cause infantile hypercalciuria and the association with 
FRTS has been questioned.9 A unique aspect of PT energy utilization was highlighted by 
our discovery of the molecular basis of FRTS type 3, where a heterozygous missense 
mutation in EHHADH (encoding enoyl-CoA hydratase and 3-hydroxyacyl CoA 
dehydrogenase) impairs mitochondrial fatty acid oxidation.10, 11 Whilst this defect is global it 
only manifests in the PT, as the PT does not utilize glucose for energy generation, exposing 
the dependency on fatty acid oxidation.12 Patients typically present in childhood with rickets 
and the biochemical abnormalities. In contrast to FRTS1, however, no progressive CKD has 
been observed.13 FRTS4 is caused by a specific mutation (R76W, also annotated as R63W, 
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depending on reference sequence) in the transcription factor HNF4A.14 Mutations in this 
gene are associated with abnormalities in insulin secretion, typically hyperinsulinemic 
hypoglycemia manifesting in the neonatal period and diabetes (MODY type 1) later in life. 
Consequently, patients with FRTS4 usually manifest shortly after birth with hypoglycemia 
and subsequent investigations then reveal the FRTS.15, 16 The association of FRTS4 with 
only this one specific mutation (all other described HNF4A mutations are only associated 
with altered insulin secretion) raises interesting question over the specific role of R76 for the 
function of HNF4A in the maintenance of proximal tubular function, but so far, no insights 
have been published. 
The bulk of sodium in the PT is taken up by the apical Na+-H+ exchanger NHE3, in this way 
linking sodium and thus volume homeostasis with acid-base homeostasis.17 Given this 
important role, one might have expected a severe form of a salt-losing tubulopathy and 
proximal acidosis with loss of function of this transporter. Instead, recessive mutations in the 
encoding gene SLC9A3 are associated with congenital sodium diarrhea (OMIM #616868).18 
Only 2 of the 7 reported patients with available data exhibited acidosis. While also 
presenting with diarrhea, mice lacking Nhe3 function do show also evidence of salt wasting 
and acidosis.19 . To better dissect the respective renal and/or intestinal contribution to the 
acidosis, a renal specific knock-out was generated, which confirmed renal bicarbonate 
wasting, albeit with only mild acidosis.20 These studies confirm the important role of NHE3, 
yet, at least in PT, the loss of function may be partially compensated by other NHE isoforms, 
such as NHE8.21  
Another important sodium transporter in PT is the Na+-PO4- cotransporter NaPi-IIa, encoded 
by SLC34A1. Initially, a homozygous loss-of-function mutation was reported as the cause of 
FRTS type 2 in 2 siblings.8 Yet, no further patients with FRTS and SLC34A1 mutations have 
been identified since. Instead recessive loss-of-function mutations in this gene are 
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recurrently found as the cause of infantile hypercalcemia with nephrocalcinosis (OMIM 
#616963).9 Moreover, heterozygous mutations have been associated with 
hypophosphatemic nephrolithiasis (OMIM # 612286),22 similar to the hypophosphatemic 
rickets with hypercalciuria caused by heterozygous mutations in SLC34A3, encoding NaPi-
IIc (OMIM #241530). Presumably, the hypophosphatemia-mediated suppression of FGF23 
leads to increased 1-alfa hydroxylation of cholecalciferol with resultant hypercalcemia and 
hypercalciuria.23  
Of interest is also the sodium-glucose cotransporter SGLT2, encoded by SLC5A2. 
Recessive mutations in this transporter cause isolated renal glucosuria (OMIM #233100), 
and it provides an example of the enormous benefits the study of a rare disorder can have 
for common disorders. Patients with isolated renal glucosuria can lose well over 100 g of 
glucose daily, yet with no apparent detrimental consequences.24-26 In fact, in an era of 
affluence in which obesity and diabetes have become major threats to public health, the loss 
of sodium and glucose in the urine may be beneficial and SGLT2 thus became an attractive 
therapeutic target.25 Inhibitors of SGLT2, the gliflozins, are now available and seem to 
provide substantial benefits in the management of diabetes with not only improved glucose 
control but also reduced cardiovascular mortality and diabetic nephropathy.27  
 
Two further transporters affecting sodium reabsorption in PT are associated with diseases: 
recessive mutations in SLC4A4, encoding a basolateral Na-bicarbonate co-transporter 
NBC1 cause proximal tubular acidosis with eye findings (OMIM # 604278) and recessive 
mutations in carbonic anhydrase 2, encoded by CA2 cause proximal tubular acidosis with 
osteopetrosis (OMIM #259730). While CA2 does not transport sodium directly, it clearly 
affects the availability of H+ for the apical Na+-H+ exchange. However, except for occasional 
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case reports and case series, very little new data are available for these very rare 
disorders.28, 29 
Clinical controversies: 
Patients with FRTS exhibit proteinuria. This primarily reflects “tubular” proteinuria, i.e. the 
impaired reabsorption of filtered proteins, but in some patients proteinuria reaches the 
nephrotic range. While the exact amount of physiological tubular protein (including albumin) 
reabsorption remains controversial and may approach several grams per day,30 some 
patients also show evidence of glomerular damage.31, 32 Should these patients be treated 
with so called anti-proteinuric drugs, such as ACEi or ARB? Given the impaired sodium 
reabsorption in FRTS and thus risk of loss of volume homeostasis, are such treatments, 
which are generally recommended for proteinuria in chronic kidney disease, of benefit to 
patients with rare tubular salt-losing disorders?  
 
Thick Ascending Limb 
From the PT, the primary urine traverses into the thin limb of the loop of Henle, So far, no 
human disorders have been associated with altered salt transport here, so we will 
concentrate on the thick ascending limb (TAL, fig 3). 
The study of rare disease has greatly enhanced our understanding of this nephron segment, 
mainly through investigations into Bartter syndrome (BS) and familial hypomagnesemia with 
hypercalciuria and nephrocalcinosis (FHHNC). The electroneutral furosemide-sensitive Na+-
2Cl--K+ cotransporter (NKCC2), encoded by SLC12A1, is the key apical sodium transporter. 
Mutations in this gene cause BS type 1 (OMIM #601678). Function of NKCC2 is dependent 
on apical recycling of potassium through the potassium channel ROMK, encoded by KCNJ1. 
Consequently, mutations in this channel are the cause of BS type 2 (OMIM #241200). 
Together, these two transport proteins generate the lumen positive transepithelial potential, 
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which drives the paracellular absorption of cations, including Ca++ and Mg++, a pathway lined 
by the Claudins 16 (CLDN16) and 19 (CLDN19). Mutations in these genes cause FHHNC 
(OMIM #248250 and #248190, respectively). Thus, reabsorption of divalent cations in TAL is 
linked to sodium transport via NKCC2. Yet, the claudins also facilitate paracellular sodium 
reabsorption and, at least in the mouse model, FHHNC is associated with renal salt 
wasting.33 Basolateral exit of sodium and chloride is mediated by the Na+-K+-ATPase and 
the chloride channel CLCNKB, respectively. Recessive mutations in CLCNKB are the cause 
of BS type 3 (OMIM #607364). It is likely, that the close homologue CLCNKA contributes to 
salt reabsorption in TAL, explaining the typically more severe phenotype in patients lacking 
Barttin (BSND), the obligate subunit for both CLCNK homologues, mutations in which cause 
BS type 4A (OMIM #602522). A similar severe phenotype occurs with loss-of-function 
mutations in both chloride channels (BS type 4B, OMIM #613090). In contrast to these 
observations in patients, data from mouse studies do not support the notion of a substantial 
contribution of ClC-K1 (the mouse orthologue of CLCNKA) to salt reabsorption in TAL.34, 35 It 
is important to note that CLCNKB and Barttin constitute the key pathway for basolateral 
chloride exit also in the distal convoluted tubule (DCT, see below) and thus can 
phenotypically resemble a mixed TAL/DCT disorder.34, 36 
Previously, a terminology had been proposed to separate Bartter syndromes into so-called 
antenatal BS (BS types 1, 2 and 4) and “classic” BS (BS type 3) with presentation later in 
childhood.37 Indeed, retrospective reviews clearly show a trend for more severe antenatal 
presentation in BS types 1,2, and 4 compared to type 3.4, 38 Yet, there is a wide spectrum of 
severity in all forms of Bartter syndrome: some patients with BS type 1,2 or 4 present only 
later in life, including adulthood, whereas some patients with BS type 3 have a severe 
antenatal presentation with prematurity as early as 22 weeks of gestation and 
polyhydramnios treated with amniocentesis.39-43There are some data for CLCNKB 
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suggesting that mutation type may influence the phenotype with mutations affecting the 
Barttin-binding site, the dimerization interface or the selectivity filter causing more severe 
dysfunction.44 Yet, the most common mutation in CLCNKB is a whole gene deletion, which 
can be associated with the whole phenotypic spectrum. One recent review of 30 patients 
with BS type 3 found no evidence for a genotype-phenotype association,45whereas in a 
larger series of 115 patients an association of complete loss-of-function mutations with age 
at onset was seen.46  
 
Regulation by MAGED2 
Previously, transient forms of antenatal BS have been described, but it was only recently 
that a genetic explanation for a subset of these patients has been identified: loss-of-function 
mutations in the melanoma-associated antigen-D2 (MAGED2).47 It appears that the encoded 
protein is an important regulator of tubular salt reabsorption in TAL and distal convoluted 
tubule (DCT) in the ante- and perinatal period, but not thereafter. The gene maps to the X-
chromosome and pregnancies with affected boys are prominently characterized by severe 
polyhydramnios.47 After delivery, polyuria persists with hypokalemic alkalosis, but symptoms 
resolve spontaneously during the first few months of life. Why there seems to be separate 
regulation of tubular transport before and after birth and what role exactly MAGED2 plays in 
this process, remains to be elucidated. 
 
Macula densa, tubuloglomerular feedback and hyperreninism 
Hypertrophy of the juxtaglomerular apparatus (JGA) was already part of the original 
description of BS.48 The JGA is at the interface of glomerular and tubular function and 
mediates tubuloglomerular feedback (TGF) and essentially constitutes the “volume sensor” 
of the kidney, where based on tubular sensing, renin release and glomerular filtration are 
 
 
11 
 
regulated.49 The tubular component of the JGA is the macula densa and chloride transport is 
a key initial signaling pathway: decreased chloride availability indicates inadequate filtration 
and leads to activation of the TGF with consequent renin release and afferent arteriolar 
dilatation with hyperfiltration through a number of intermediate steps, most prominently the 
production of prostaglandin E2 (PGE2) by cyclooxygenase-2 (COX2).50, 51 This elevated 
COX2 activity is the basis for treatment of BS with prostaglandin synthesis inhibitors. 
Importantly, since macula densa cells are part of the TAL, mutational effects are present 
here as well, leading in essence to a short-circuit of TGF, as chloride reabsorption is 
genetically impaired in BS. Consequently, renin release and regulation of filtration are 
essentially uncoupled from volumes status in BS, as the volume sensor is defect. PGE2 
production appears be highest in BS type 1 and 2, which led to the proposal of the term 
“Hyperprostaglandin E syndrome” for these BS subforms.37 Yet, despite the lower 
prostaglandin levels, the hypokalemic alkalosis is typically much more pronounced in BS 
type 3 compared to types 1 and 2.38, 52 The reasons for this are not quite clear: is it, because 
CLCNKB is expressed also beyond TAL in the distal convoluted tubule, thus impairing salt 
transport in two nephron segments?35 But why then is it typically the “milder” form with later 
onset? Do patients with BS type 3 have higher aldosterone levels, despite lower PGE2? If 
so, what triggers the aldosterone production? Further investigations are needed to better 
understand the often dramatic electrolyte abnormalities in BS3. 
 
Clinical controversies 
The wide spectrum of clinical severity in all types of BS has led to controversies regarding 
the terminology: should a classification system be based on the clinical phenotype, 
distinguishing between “antenatal” BS (sometimes also referred to as “Hyperprostaglandin E 
syndrome”) and “classic” BS?53 But where exactly is the separation? Does a patient born at 
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36 weeks have antenatal or classic BS? Or should it be based on the clinical similarity to the 
effects of diuretics and thus the predominantly affected nephron segment: loop versus DCT 
disorder?37 But where do patients belong to, who initially have a BS-like phenotype but later 
fit a Gitelman syndrome (GS) type, as can be seen in patients with CLCNKB mutations?36 
Do they switch classification and thus are told at some point that they have a different 
diagnosis then initially assigned? Or should we stick with the genetic classification, as in this 
review? But even there is heterogeneity: BS type 5 is referred to by some authors as related 
to mutations in CASR, by others to combined mutations in CLCNKA and CLCNKB and, 
more recently it has been assigned by OMIM to the transient BS associated with mutations 
in MAGED2 (see table 1).37, 54 It gets even more confusing when clinical and genetic criteria 
are combined, so that antenatal BS becomes synonymous with BS types 1,2 and 4 and 
classic BS with type 3.37 In this system, a patient with adult presentation and mutations in 
SLC12A1 would be categorized as antenatal BS, whereas the premature baby with 
CLCNKB mutations would have classical BS. Similarly, a baby with BS born prematurely 
after a pregnancy complicated by polyhydramnios could be classified either as antenatal or 
classical BS, depending on the underlying genetic cause. While such classification system 
captures well the majority of patients, in a substantial minority (including the 20-30% of 
patients with BS type 3 with antenatal presentation) the clinical and genetic criteria 
diverge.38, 46 
Potentially severe complications related to the electrolyte abnormalities, such as cardiac 
arrhythmias have been described in BS.55 We recently described a case of BS type 4 with 
such dramatic alkalosis that not only was there impaired breathing (“renal apnoea”) but there 
also seemed to be a more generalized enzyme dysfunction.56 Alkalosis is typically most 
severe in patients with BS type 3 and 4, potentially related to chloride depletion, 
emphasizing the need to use chloride containing salt supplementation.57 Indeed, 
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stabilization of volume status with salt and water should always be the first therapeutic aim. 
Yet, even the combined use of such supplementation with prostaglandin synthesis inhibitors 
is often not sufficient to achieve sustained normalization of electrolyte abnormalities. This is 
most dramatically seen in BS type 4.58 So, what level of potassium can we consider safe 
and should we aim for? Is a wildly swinging potassium level associated with large doses of 
intermittent supplementation safer than a stable but very low level? The hypokalemic 
alkalosis can be improved with the use of K+-sparing diuretics, but this is controversial: BS is 
primarily a salt wasting disorder and the salt wasting will be compounded by the use of K+-
sparing diuretics, putting the patient at risk of severe hypovolemia. While we can measure 
potassium very easily and thus may feel prompted to treat abnormalities, hypovolemia is 
much more difficult to express in exact numbers. Could some of the reported sudden 
collapses in salt-losing tubulopathies be related to hypovolemia rather than hypokalemia, for 
instance, when the patient develops vomiting and/or diarrhea, compounding the renal with 
intestinal salt losses? However, given the above discussed short-circuit of the JGA in BS, 
where renin production appears to be uncoupled from volume status, the use of K+-sparing 
diuretics may be justified, as long as volume is sufficiently supported by fluid and 
pharmacologic salt supplementation. Further studies to assess the efficacy of these drugs 
are needed. If used, amiloride may be preferable to mineralocorticoid antagonists, such as 
spironolactone, as the alkalosis may not only be mediated by H+ secretion in the 
aldosterone-sensitive distal nephron alone, but also by NHE3 in TAL, which is also inhibited 
by amiloride, albeit with a much lower affinity compared to ENaC.59  
Obviously, this controversy extends beyond potassium-sparing diuretics, but also concerns 
the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. 
While not commonly used in BS, physicians may be inclined to use them in those patients, 
who develop proteinuria, especially if the biopsy reveals glomerulosclerosis.46 Whether 
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these medications at this stage can help protect kidney function that could justify the risk of 
hypotension is yet another open question. 
 
Another treatment dilemma occurs in patients with BS complicated by a nephrogenic 
diabetes insipidus (NDI)-like phenotype. The TAL is critical for urinary dilution and the 
establishment of the interstitial concentration gradient.60 Consequently, isosthenuria, the 
inability to either dilute or concentrate the urine would be expected in BS and is indeed 
present in many of them. However, there are some patients with NDI-like features, i.e with a 
urine osmolality <200 mosm/kg and an inability to concentrate the urine after administration 
of DDAVP.61, 62 Misdiagnosis of such BS patients as primary NDI has been reported and we 
therefore suggested the term “secondary inherited NDI”.63 Presumably, the urinary dilution is 
mediated by a hypertrophied DCT, but the unresponsiveness to DDAVP remains to be 
clarified. Clinically, these patients present a treatment dilemma: salt supplementation is 
usually a key component of the treatment of BS, but contraindicated in NDI. In our own 
clinical experience, salt supplements are poorly tolerated by these patients, and often 
associated with hypernatremia and increased thirst (unpublished own observations). 
 
Since the discovery of elevated renal production of prostaglandins and their role in 
mediating elevated renin and aldosterone levels, suppression of PGE2 production by 
prostaglandin synthesis inhibitors is generally accepted as beneficial in the treatment of BS, 
at least during the first few years of life.64, 65 Yet, during later childhood, this effect appears to 
be less pronounced and prostaglandin synthesis inhibitors are often weaned or withdrawn. 
Why is this? Is it because patients can now self-regulate their salt and water intake and thus 
better self-maintain homeostasis? Or are there developmental changes in the regulation of 
tubular salt reabsorption that make prostaglandins less relevant? The discovery of BS type 5 
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and the causative gene MAGED2 clearly provide evidence for developmental changes in the 
first months of life in the regulation of tubular salt transport.66  
In the infantile period, clinical observations demonstrate an often dramatic improvement 
from PGE2 inhibition: it reduces polyuria, improves the electrolyte abnormalities and 
ameliorates the failure-to-thrive.64 However, which drug should be used? The most 
commonly prescribed drug in BS is indomethacin due to its described efficacy with respect 
to decreased polyuria, improved growth and electrolyte control.67, 68 Yet, it can also be 
associated with severe side effects, especially gastrointestinal, such as gastric ulcer, 
necrotizing enterocolitis and gut perforation.69 Moreover, long-term use as pain medication is 
associated with chronic kidney disease.70 The identification of the critical role of COX2 in the 
excess production of prostaglandins in BS, established selective COX2 inhibitors, the so-
called “coxibs” as a promising new treatment option.71 Indeed, successful treatment with 
these drugs has been recurrently reported.69, 72, 73 However, with the realization of the 
increased cardiovascular mortality with selective compared to non-selective COX inhibitors 
at least in adults and the subsequent withdrawal of rofecoxib from the market, the use of the 
coxibs in BS has remained controversial. In one retrospective review of 28 patients with BS 
or GS, rofecoxib use was associated with higher blood pressure compared to indomethacin, 
although in both groups blood pressure was still below the average.74 It remains to be 
determined, what poses the greater threat to patients with BS: the risk of gastrointestinal 
and/or renal side effects or the potentially increased cardiovascular mortality. Yet, even with 
regards to the renal side effects, there is some controversy: Retrospective reviews have 
revealed that a substantial subset of patients (up to 25%) with BS develop chronic kidney 
disease.46, 52 The reasons for this may include prematurity and indomethacin nephrotoxicity. 
Yet, interestingly, if biopsies are performed, these typically do not reveal the tubulointerstitial 
changes expected from indomethacin toxicity, but often glomerulosclerosis.46, 75 
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Consequently, it has been speculated that the persistent elevation of prostaglandins with 
consequent glomerular hyperfiltration and elevated renin and aldosterone may contribute to 
this glomerular damage and that life-long treatment with prostaglandin synthesis inhibitors 
may therefore actually protect, rather than impair long-term kidney function.71, 75, 76 Lastly, 
the antenatal treatment of BS has been reported in isolated cases.77, 78 Yet, whether there is 
true benefit from this early treatment which justifies the increased risk of potential 
complications such as necrotizing enterocolitis remains controversial. 
 
Distal Convoluted Tubule 
Impaired salt reabsorption in the distal convoluted tubule (DCT) is associated with two 
disorders: GS (OMIM #263800) and EAST syndrome (also called SeSAME, OMIM 
#612780).79-81 GS is probably the most common renal salt wasting disorder with an 
incidence of around 1:25,000 and often considered a mild disorder. It is typically diagnosed 
during adolescence or adulthood, often incidentally, when blood tests are obtained for other 
reasons and hypokalemia is noted. Yet, there are many patients who report significant 
symptoms, such as severe fatigue, lack of stamina and impaired quality of life.82 
Interestingly, the severity of electrolyte abnormalities in these patients is not significantly 
different from those with minor or no symptoms.83 Later in life, patients may develop 
complications, such as chondrocalcinosis and sclerochoroidal calcifications. Surprisingly, the 
development of hypertension has been reported in isolated adult patients with GS and one 
large retrospective study suggests that there may also be an increased risk of type 2 
diabetes and chronic kidney disease.83, 84  
From an isolated renal perspective, EAST syndrome is essentially indistinguishable from GS 
and the severity of the disorder is primarily determined by the extrarenal manifestations: 
generalized seizures are commonly the presenting syndrome in infancy, yet the epilepsy 
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typically improves with time and many patients have several years with little or no seizure 
activity, although with later emergence of focal epilepsy.85 While KCNJ10 is expressed in the 
eye and patients have subtle, but distinct changes on electroretinograms, these do not lead 
to any apparent symptoms.86 It is the degree of ataxia, especially with the associated 
speech dyspraxia that determines mostly the disability of patients with some patients 
virtually unable to communicate, as both speech and written communication are impaired by 
the movement disorder.87 This decreased expressive ability may have contributed to the 
stigmatising label of “mental retardation”, part of the acronym “SeSAME”. 
The identification of animal models of EAST syndrome may facilitate the generation of new 
treatments for this severe multisystem disorder. 88-90 
The discovery of EAST syndrome established the critical role of KCNJ10 for the function of 
the DCT and prompted the consideration for the DCT as the renal “K+-sensor“ to maintain 
potassium homeostasis.91 Hypokalemia leads to hyperplarization of the basolateral 
membrane of DCT cells with consequent enhanced chloride exit through CLCNKB. The 
resultant decreased intracellular chloride concentration activates the WNK-SPAK pathway, 
which in turns leads to phosphorylation and thus increased activity of the NaCl cotransporter 
NCC, so that little sodium remains to be delivered to the collecting duct (CD).92 Conversely, 
in hyperkalemia, sodium uptake in DCT will be decreased and more sodium is delivered to 
the CD where sodium reabsorption can be balanced by potassium-secretion (see fig. 4). The 
WNK kinases WNK4 and WNK1 are important regulators for the relative abundance of 
sodium reabsorption in DCT versus CD and the interplay between sodium and potassium is 
increasingly recognized as a key element not only for potassium homeostasis, but also 
blood pressure regulation.93, 94 
The expression of CLCNKB in DCT also explains why patients with BS type 3 can 
phenotypically resemble GS.34, 46 Patients with HNF1B mutations can also phenocopy GS, 
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presenting the typical electrolyte profile, sometimes with only minor radiological 
abnormalities of the kidneys, leading to a potential misdiagnosis.95, 96  
 
Clinical controversies 
The same potentially serious complications of hypokalemic alkalosis reported in BS have 
also been associated with GS. However, as GS does not involve the JGA and thus TGF is 
intact, potential elevations of prostaglandins, renin and aldosterone should reflect 
physiologic compensation for the salt losses in DCT. Following this understanding of the 
pathophysiology, such activation of the renin-angiotensin system should be suppressible by 
sufficient salt supplementation and consequently, treatment with prostaglandin synthesis 
inhibitors and/or K+-sparing diuretics should be avoided in GS. Nevertheless, a beneficial 
effect of such drugs in GS has been reported.97 Apparently, despite our insights into renal 
pathophysiology, we still do not fully understand the development of symptoms in GS. Yet, 
given the augmented salt wasting with amiloride and the potential nephrotoxic and 
gastrointestinal side effects of prostaglandin synthesis inhibitors, their use has been 
cautioned in an expert consensus statement on GS.83 
As in BS, it remains controversial what level of plasma potassium is acceptable in GS. 
Similarly, to what degree should magnesium levels be normalized? This is especially 
important in EAST syndrome, as the seizures may be attributed to hypomagnesemia. Yet, in 
our experience, seizures occur in EAST syndrome independent of plasma magnesium levels 
and, similarly, symptoms of GS cannot be correlated with the degree of electrolyte 
abnormalities.83, 85 An increase in plasma levels after oral supplementation results in 
increased glomerular filtration and thus increased renal losses, leading to a virtual 
impossibility in many patients to normalize plasma levels with oral supplementation.  
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Collecting Duct 
The CD is the final part of the nephron and although quantitatively, the smallest proportion of 
filtered sodium is reabsorbed here, this is the tubular segment where final decisions about 
sodium and water reabsorption are being made and reabsorption is most highly regulated. 
As there is no further segment downstream to compensate, dysfunction in this segment can 
be most devastating, as seen in the autosomal recessive form of pseudohypoaldosteronism 
type 1 (arPHA1, OMIM #264350), caused by loss-of-function mutations in any of the 
subunits of the epithelial sodium channel ENaC. Affected infants typically present in the first 
few days with excessive weight loss and are found to have life-threatening hypovolemia with 
hyperkalemia and acidosis. Interestingly, PHA1 is the only salt-losing tubulopathy that 
typically presents with hyponatremia, presumably because the severe hypovolemia leads to 
release of anti-diuretic hormone. As ENaC is also expressed in lungs and skin, patients with 
arPHA1 can also suffer from cystic fibrosis-like lung disease, as well as from a miliary skin 
rash. In contrast, the autosomal dominant form (adPHA1, OMIM #177735) has exclusive 
renal manifestations. It is caused by heterozygous mutations in NR3C2, the gene encoding 
the mineralocorticoid receptor. Affected patients typically present in the first month of life 
with insufficient weight gain and subsequent blood tests show hyponatremia, hyperkalemia 
and metabolic acidosis. While manifestations are usually not as severe as in arPHA1, they 
can be also life-threatening98. Interestingly, symptoms resolve spontaneously later on, in our 
own experience even as early as during infancy. The reasons for this spontaneous 
improvement remain to be elucidated. Studies of adult carriers of adPHA1, however, show 
elevated renin and aldosterone, as well as cortisol levels compared to unaffected family 
members, suggesting that despite the absence of overt symptoms, haploinsufficiency of 
NR3C2 may have subtle lifelong consequences.99, 100 
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Summary 
Much has been learned about salt-losing tubulopathies, catalyzed by the recent advances in 
genetics, which has led to the identification of most of the underlying genes. However, 
clinical observations in genotyped patients continue to raise questions about specific 
aspects of the roles of these genes. Most importantly, despite the ever more detailed 
insights into human physiology, treatment for most these disorders is highly variable 
between physicians and sometimes even controversial. Fundamental questions, such as 
whether hypokalemia or hypovolemia poses a graver threat to the patient with Bartter and 
Gitelman syndrome remain open. Due to the rarity of these disorders, solid clinical evidence 
is usually not available and it is the anecdotal experience that often influences the individual 
physician.101 National and international efforts, such as the UK registry for rare renal 
diseases (www.rarerenal.org), the KDIGO expert consensus conference on Gitelman 
syndrome83 and the European Reference Network for rare diseases 
(http://ec.europa.eu/health/rare_diseases/european_reference_networks/erf_en) are 
important initiatives to improve the systematic collection of evidence and provide a 
framework for the development of rational and improved treatments. In this review, we have 
tried to highlight controversial topics in the management of these disorders, which could 
inform the developmental of future clinical trials. 
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Table and Figure legends 
Table 1- Genetics of primary renal salt (NaCl) losing nephropathies and their typical 
clinical characteristics 
Listed are inherited salt wasting disorders, including the underlying gene/protein and clinical 
characteristics. Note that most of these clinical disorders can have a wide spectrum of 
severity. Typical clinical findings listed thus reflect symptoms seen in most, but not 
necessarily all patients. 
Data from OMIM, HUGO, NCBI (build 35.1). AD = Autosomal dominant; AR = autosomal 
recessive.  
^ recessive mutations in SLC34A1 have also been reported as a cause of FRTS2 (OMIM 
613388, see text) 
*: These forms of Bartter syndrome also affect salt reabsorption in the distal convoluted 
tubule 
 
Table 2: Clinical controversies in salt-losing tubulopathies 
Listed are clinical controversies discussed in this review. These controversies need 
clarification through clinical trials and/or expert consensus. ACEi: Angiotensin-converting 
enzyme inhibitors, COXi: cycloxygnease inhibitors, NDI: nephrogenic diabetes insipidus. 
 
Fig. 1. Sodium and water reabsorption along the nephron. Knockouts of distinctive proteins 
in particular nephron segments lead to distinctive disease in man as indicated. PHA1: 
Pseudohypoaldosteronism type 1 
 
Fig. 2. Simplified diagram of a proximal tubular (PT) cell. Sodium reabsorption in the PT is 
mainly accomplished by NHE3, which exchanges sodium for protons. Other sodium-coupled 
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transporters use the chemical and electrical gradient of sodium for the reabsorption of 
molecules (X stands for, e.g., glucose, amino acids, phosphate). 
 
Fig. 3. Simplified diagram of a thick ascending limb (TAL) cell. Sodium is reabsorbed 
electroneutrally via NKCC2 (defect in Bartter type I), together with one potassium and two 
chloride ions. The transporter can only function with all 4 ions bound and due to its 
luminal concentration, potassium binding becomes the rate-limiting step. Therefore, 
potassium is recycled through the potassium channel ROMK1 (defect in Bartter type II) to 
ensure an adequate luminal supply of potassium. This also generates a lumen positive 
transepithelial potential, providing the driving force for paracellular absorption of calcium and 
magnesium. Sodium exits the cell on the basolateral (blood side) via the Na-K-ATPase, 
while chloride exits through the chloride channels CLCNKB (defect in Bartter type 3) and 
CLCNKA; both require Barttin (defect in Bartter type 4) for proper membrane localization. 
NKCC2 can be inhibited by loop diuretics, such as furosemide. 
 
Fig. 4. Simplified diagram of a distal convoluted tubule (DCT) cell. Sodium is reabsorbed 
electroneutrally via a sodium-chloride cotransporter (NCC) and can then exit towards the 
blood side via the Na-K-ATPase, while chloride can pass through the basolateral chloride 
channel CLCKNB. KCNJ10 indirectly regulates Na-K-ATPase activity by providing a supply 
of potassium dependent on basolateral potassium concentration. NCC can be inhibited by 
thiazides. Impaired salt reabsorption in DCT indirectly affects magnesium uptake via 
TRPM6, explaining the renal magnesium wasting for salt-losing disorders of the DCT. 
 
Fig. 5. Simplified diagram of a principal cell and type 1 intercalated cell in the cortical 
collecting duct (CCD). Sodium reabsorption occurs electrogenic through ENaC and Na-K-
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ATPase and thus facilitates potassium and proton secretion through ROMK and the H+-
ATPase, respectively. Aldosterone indirectly affects the activity of these proteins via the 
mineralocorticoid receptor MRCR. ENaC can be inhibited by amiloride. 
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Table 1. Genetics of primary renal salt-losing nephropathies and pertinent clinical characteristics 
Nephron 
segment 
Disorder OMIM Gene Protein Inheritance Typical clinical findings 
 
Proximal tubule Fanconi Renotubular 
syndrome type 1; FRTS1 
134600 ? ? AD rickets, progressive chronic kidney 
disease 
Infantile hypercalciuria 2 ^ 613388 SLC34A1 NaPi-IIa AR Hypercalciuria, nephrocalcinosis 
Hypophosphatemic rickets 
with hypercalciuria 
241530 SLC34A3 NaPi-IIc AR/AD Hypercalciuria, nephrocalcinosis 
Fanconi Renotubular 
syndrome type 3; FRTS3 
615605 EHHADH EHHADH AD rickets, no kidney failure 
Fanconi Renotubular 
syndrome type 4; FRTS4 
600281    Congenital hyperinsulinism, later MODY, 
rickets 
Renal glucosuria 233100 SLC5A2 SGLT2 AR/AD Glucosuria 
Proximal renal tubular 
acidosis with eye findings 
604278 SLC4A4 KNBC AR Metabolic acidosis, eye abnormalities 
(corneal opacities, band keratopathy, 
cataract, glaucoma), mental impairment 
Osteopetrosis with renal 
tubular acidosis 
259730 CA2 CA2 AR Osteopetrosis, cerebral calcifications, 
metabolic acidosis 
Thick 
ascending 
Limb 
Bartter syndrome type I 601678 SLC12A1 NKCC2 AR Prematurity, polyhydramnios 
nephrocalcinosis, hypokalemic alkalosis, 
iso- or hyposthenuria 
Bartter syndrome type II 241200 KCNJ1 ROMK1 AR Prematurity, polyhydramnios 
nephrocalcinosis, transient 
hyperkalaemia, then hypokalemic 
alkalosis, iso- or hyposthenuria 
Bartter syndrome type III* 607364 CLCNKB ClC-Kb AR Severe hypokalemic hypochloremic 
alkalosis 
Bartter syndrome type IVA* 602522 BSND Barttin AR Prematurity, polyhydramnios, 
sensorineural 
deafness,  
severe hypokalemic hypochloremic 
alkalosis, iso- or hyposthenuria 
Bartter syndrome type IVB* CLCNKA, 
CLCNKB 
ClC-Ka, 
ClC-Kb 
AR 
Bartter syndrome type 5* 300971 MAGED2 MAGED2 XR Severe polyhydramnios, transient salt 
wasting 
Autosomal dominant 
hypocalcemic hypercalciuria 
 CASR CASR AD Hypocalcemic hypercalciuria, that can 
be complicated by hypokalemic alkalosis 
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Distal 
convoluted 
Tubule 
Gitelman syndrome 263800 SLC12A3 NCC AR Hypokalemic alkalosis, hypocalciuria, 
hypomagnesemia 
EAST Syndrome 612780 KCNJ10 Kir4.1 AR Epilepsy, ataxia, sensorineural 
deafness, hypokalemic alkalosis 
Cortical 
collecting 
Duct 
Autosomal dominant 
pseudohypoaldosteronism 
type I 
177735 NR3C2 MR AD Transient neonatal salt wasting 
with hyponatraemia, 
hyperkalemia, acidosis 
Autosomal recessive 
pseudohypoaldosteronism 
type I 
264350 SCNN1A 
SCNN1B 
SCNN1G 
ENaC 
alpha 
ENaC 
beta 
ENaC 
gamma 
AR Hyponatremia, hyperkalemia, acidosis, 
pathological sweat test, lung disease 
 34 
Table 2: Clinical controversies 
Tubular Segment Clinical controversies 
Proximal Tubule Do anti-proteinuric drugs, such as ACEi protect kidney function, if proteinuria is of 
tubular origin? 
Thick ascending limb Is salt supplementation beneficial in patients with secondary NDI? 
Which COXi inhibitor provides best efficacy with least side effects: indomethacin, 
ibuprofen or celexocib? 
Should COXi be weaned off during school age or should they be maintained life-
long? 
Is antenatal treatment of BS beneficial? 
Thick ascending limb and distal 
convoluted tubule 
What is the best classification for BS and GS? 
What is the lower limit of plasma potassium concentration that can be considered 
safe? 
Are potassium-sparing diuretics beneficial? 
Are anti-proteinuric drugs indicated in patients who have developed proteinuria 
What is the lower limit of plasma magnesium concentration that can be considered 
safe? 
Distal convoluted tubule Is salt supplementation alone sufficient to normalize renin and aldosterone levels? 
 
